MINNEAPOLIS, Dec. 12,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH), a global life sciences company providing innovative tools
and bioactive reagents for the research and clinical diagnostic
communities today announced a partnership with MedSanTek. Under the
agreement, MedSanTek becomes the distributor of Bio-Techne's
R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell
Diagnostics (ACD), and Asuragen brands across Turkey.
Founded in the late 2000s, MedSanTek is a leading in vitro
diagnostics and research products distributor, serving Turkey and Azerbaijan. Partnering with global brands, the
company provides high-quality solutions in molecular biology,
immunology, cancer research, cell therapy, and more, earning a
reputation for innovation and customer satisfaction in advancing
science and healthcare.
"As MedSanTek's founder, I'm thrilled to partner with Bio-Techne
to bring their world-class products—antibodies, proteins, assays,
and diagnostic kits—to Turkey and
Azerbaijan's biotechs, labs, and
hospitals," said Mr İbrahim Selçuk, Founder & General Manager
of MedSanTek Co. "Since our founding, we've earned a reputation for
quality, timely delivery, and strong customer support. With a
specialized team and a network across major cities, we remain
committed to mutual success and advancing scientific research."
"We are excited to partner with MedSanTek to expand the reach of
our products and services in the important Turkey and Azeri markets," said Dr. Peter
Schüßler, Vice President and General Manager EMEA. "MedSanTek's
industry expertise and knowledge of the local diagnostics and life
science research markets, paired with Bio-Techne's innovative
portfolio is the ideal combination to enable advances in science
and medicine in Turkey and
beyond."
For more information about Bio-Techne and its range of products
and services, visit our Website.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit http://www.bio-techne.com
or follow the Company on social media at Facebook, LinkedIn,
Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
Medsantek Life Sciences Contact
medsantek@medsantek.com.tr
ergun@medsantek.com.tr
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-new-distribution-agreement-with-medsantek-to-expand-access-to-portfolio-across-turkey-302329354.html
SOURCE Bio-Techne Corporation